Money already collected for work not yet done: the company is sitting on customer-funded obligations that dwarf what it
The model's full reasoning — Q1 2017 call → NOThe question asks whether management describes customers/counterparties having already put money or irreversible commitment into the company for things not yet delivered, and whether management treats that accumulated unearned obligation as large relative to current business, with discharging it now the central task. Looking at the transcript, there are several instances of upfront payments and milestones received for work not yet done: 1. Bayer paid $75 million to advance IONIS-FXIRx and IONIS-FXI-LRx. Beth says: "We generated $75 million in Bayer advance both IONIS-FXIRx and IONIS-FXI-LRx. And we recognized more than $65 million of the $75 million payment as revenue in the first quarter. We will amortize the remainder as we perform the development activities for these 2 drugs." So Bayer paid ahead, and Ionis still owes the development work. The remainder is deferred/unearned. 2. Novartis collaboration: "we received $175 million from our collaboration with Novartis. Under this collaboration, Novartis paid us a $75 million upfront payment and made a $100 million equity investment in Ionis at a substantial premium. The premium represents additional revenue under the collaboration. Therefore, we will amortize the $75 million upfront payment and the premium which is $33 million, into revenue ratably as we conduct the Phase IIb studies for AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx." So Novartis paid upfront, and Ionis owes the Phase IIb studies. 3. SPINRAZA royalties - but those are earned on sales, not unearned. 4. Biogen payments - $324 million in R&D revenue already received, plus $90 million approval milestones anticipated. The $324 million was for the collaboration, presumably already earned as R&D revenue. The question is whether management treats this accumulated unearned obligation as large relative to current business, and whether discharging it is now the central task. Beth says: "We're on track to meet our 2017 financial guidance of being breakeven or profitable at the operating line on a pro forma basis and a cash balance of more than $825 million." The deferred amounts: Bayer remainder (about $10 million) and Novartis upfront + premium ($108 million to be amortized). These are being amortized ratably as work is performed.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
KOPN · Q4 2023 → YESThe question is about whether management describes customers having already put money or irreversible commitment into the company for things not yet delivered, treating that as large relative to curre...
SYM · Q3 2022 → YESThe question is about whether management describes customers having already put money or irreversible commitment into the company for things not yet delivered, treating that as large relative to curre...
VNRX · Q1 2022 → YESThe question is about whether management describes customers or counterparties having already put money or irreversible commitment into the company for things not yet delivered, treating that as large...